hepatocellular carcinoma
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) diffuse or tumors >10 cm in diameter that are not amenable to radical treatment; 2) Child-Pugh grade B or higher; 3) ECOG score 0 to 2; 4) Staging: IIIa and above; 5) Biochemical parameters: absolute neutrophil count (ANC) =1.5×10^9/L; platelet count (PLT) =75×10^9/L; hemoglobin (HGB) =8g/dL (no transfusion or no erythropoietin dependence within the last 7 days); serum albumin (HSA) =2.8g/dL; 6) No history of severe drug allergy. 7) Survival > 6 months.
Exclusion criteria
Exclusion criteria: 1) Patients treated with any other investigational drug prior to the trial; 2) Known hypersensitivity to the targeted drug, severe organ dysfunction, cardiac arrhythmia, congenital heart disease; 3) Those with incomplete vital imaging studies and incomplete records of adverse reactions; 4) Previous surgery, chemotherapy, radiotherapy and immune-related treatment; 5) other conditions that, in the judgment of the investigator, may affect the conduct of the clinical study and the determination of the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lesion size;Tumor markers;Blood routine;Tumor staging;Peripheral blood RNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood biochemistry; | — |
Countries
China
Contacts
Public ContactDuan Xuhua
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed